AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18774702 — intervention group
Group type: COMPARATOR
Intervention: Inpatient initiation of home mechanical ventilation (HMV)
Number of subjects: 28
Study 16230876 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 2102
Study 16230876 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 2102
Study 12574429 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 26
Study 12574429 — intervention group
Group type: COMPARATOR
Intervention: Elderly matched controls
Number of subjects: 26
Study 10601914 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (1 mg micronized 17beta‐estradiol daily sequentially combined with 5 or 10 mg dydrogesterone for 14 days of each 28‐day cycle during 12 months and 2 mg 17beta‐estradiol combined with 10 mg dydrogesterone thereafter for a period of 3 months)
Number of subjects: 30
Study 10601914 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 7652679 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trial (RCT)
Number of subjects: 0
Study 7652679 — intervention group
Group type: COMPARATOR
Intervention: Patient Preference
Number of subjects: 0
Study 7652679 — intervention group
Group type: COMPARATOR
Intervention: Uncommon Condition
Number of subjects: 0
Study 7652679 — intervention group
Group type: COMPARATOR
Intervention: Lack of Community Equipoise
Number of subjects: 0
Study 7652679 — intervention group
Group type: COMPARATOR
Intervention: Methodologic Issues
Number of subjects: 0
Study 7652679 — intervention group
Group type: COMPARATOR
Intervention: Surgical Preference
Number of subjects: 0
Study 2245833 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) and intrauterine insemination (IUI)
Number of subjects: 67
Study 7449382 — intervention group
Group type: EXPERIMENTAL
Intervention: TGLVP (0.5 mg and 1 mg)
Number of subjects: 28
Study 7449382 — intervention group
Group type: EXPERIMENTAL
Intervention: LVP (0.1, 0.2, and 0.4 IU)
Number of subjects: 28
Study 7449382 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug injection)
Number of subjects: 28
Study 6466531 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 10 mg pretreatment followed by 1 mg/kg suxamethonium
Number of subjects: 50
Study 6466531 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment with suxamethonium
Number of subjects: 50
Study 31714912 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (Tostran 2% gel)
Number of subjects: 136
Study 31714912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 29183257 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.2 g.kg-1 BM)
Number of subjects: 11
Study 29183257 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g.kg-1 BM)
Number of subjects: 11
Study 29183257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.07 g.kg-1 BM sodium chloride)
Number of subjects: 11
Study 26099617 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cm H2O PEEP group
Number of subjects: 44
Study 26099617 — intervention group
Group type: EXPERIMENTAL
Intervention: FORESIGHT rSO2 values in PEEP group
Number of subjects: 44
Study 26099617 — intervention group
Group type: COMPARATOR
Intervention: ZEEP group
Number of subjects: 44
Study 26099617 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 24858202 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PPROM (<25.0 weeks)
Number of subjects: 1531
Study 24858202 — intervention group
Group type: COMPARATOR
Intervention: Later PPROM (≥25.0 weeks)
Number of subjects: 1531
Study 22378800 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic preparation, specific dosage and duration not mentioned
Number of subjects: 0
Study 22378800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20570138 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular touch‐screen completion of HRQOL with feedback to physicians
Number of subjects: 286
Study 20570138 — intervention group
Group type: COMPARATOR
Intervention: Completion of HRQOL without feedback
Number of subjects: 286
Study 20570138 — intervention group
Group type: COMPARATOR
Intervention: No HRQOL assessment
Number of subjects: 286
Study 17584828 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (RU486), single dose administered during the mid-secretory phase.
Number of subjects: 0
Study 16225604 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 13
Study 16225604 — intervention group
Group type: COMPARATOR
Intervention: Untreated plaques
Number of subjects: 13
Study 12386905 — intervention group
Group type: EXPERIMENTAL
Intervention: Full of Ourselves: Advancing Girl Power, Health, and Leadership
Number of subjects: 500
Study 12386905 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 500
Study 10449105 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-alpha4 integrin antibody (natalizumab; Antegren)
Number of subjects: 72
Study 10449105 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study 7840362 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/day of oral dexamethasone for 4 days
Number of subjects: 37
Study 7840362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 2404448 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerosis
Number of subjects: 72
Study 2404448 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerosis with surgical rescue
Number of subjects: 72
Study 2404448 — intervention group
Group type: COMPARATOR
Intervention: Distal splenorenal shunt
Number of subjects: 72
Study 2404448 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal sclerosis or distal splenorenal shunt
Number of subjects: 72
Study 525066 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg piroxicam daily for two weeks (7 patients)
Number of subjects: 17
Study 525066 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg indomethacin tid for two weeks (9 patients)
Number of subjects: 17
Study 525066 — intervention group
Group type: COMPARATOR
Intervention: Overall assessments by patients and physicians
Number of subjects: 17
Study 525066 — intervention group
Group type: COMPARATOR
Intervention: Side effects due to trial treatment
Number of subjects: 17
Study 525066 — intervention group
Group type: COMPARATOR
Intervention: Laboratory test results
Number of subjects: 17
Study 29737446 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session educational intervention
Number of subjects: 254
Study 29737446 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 254
Study 27809407 — intervention group
Group type: EXPERIMENTAL
Intervention: The Transporters (TT) animated series
Number of subjects: 77
Study 27809407 — intervention group
Group type: COMPARATOR
Intervention: Control series
Number of subjects: 77
Study 27809407 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental support (with)
Number of subjects: 77
Study 27809407 — intervention group
Group type: COMPARATOR
Intervention: Parental support (without)
Number of subjects: 77
Study 27809407 — intervention group
Group type: COMPARATOR
Intervention: Typically developing children (no intervention)
Number of subjects: 77
Study 25601604 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 100 mg encapsulated, taken 2 hours prior to intercourse for 3 weeks
Number of subjects: 40
Study 25601604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24503140 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg) plus Eicosapentaenoic acid (EPA) (1800 mg)
Number of subjects: 0
Study 24503140 — intervention group
Group type: COMPARATOR
Intervention: Pitavastatin (4 mg)
Number of subjects: 0
Study 23692790 — intervention group
Group type: EXPERIMENTAL
Intervention: Medijet (MJ) system
Number of subjects: 161
Study 23692790 — intervention group
Group type: COMPARATOR
Intervention: Bubble CPAP (B-CPAP)
Number of subjects: 161
Study 19744033 — intervention group
Group type: EXPERIMENTAL
Intervention: icaridine 20%
Number of subjects: 100
Study 19744033 — intervention group
Group type: EXPERIMENTAL
Intervention: para‐menthane‐diol (PMD) 20%
Number of subjects: 100
Study 19744033 — intervention group
Group type: EXPERIMENTAL
Intervention: para‐menthane‐diol (PMD) 50%
Number of subjects: 100
Study 19744033 — intervention group
Group type: EXPERIMENTAL
Intervention: DEET 50%
Number of subjects: 100
Study 19744033 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 17478464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg once daily (o.d.)
Number of subjects: 235
Study 17478464 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg three times daily (t.i.d.)
Number of subjects: 235
Study 15361110 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 115
Study 15361110 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 115
Study 15361110 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 115
Study 11071682 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral vaporization of the prostate (TUVP)
Number of subjects: 30
Study 11071682 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 30
Study 8638525 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic nitrates (nitroglycerin, isosorbide dinitrate, isosorbide‐5‐mononitrate)
Number of subjects: 0
Study 8638525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent administration of organic nitrates
Number of subjects: 0
Study 8233745 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-HbOC combined vaccine (0.5 mL injection)
Number of subjects: 0
Study 8233745 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of DTP and HbOC (0.5 mL each in separate legs)
Number of subjects: 0
Study 2992116 — intervention group
Group type: EXPERIMENTAL
Intervention: Suloctidil (200 mg t.i.d.)
Number of subjects: 136
Study 2992116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 29300218 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV counseling and testing (HCT)
Number of subjects: 28
Study 29231546 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy group with acupuncture and huazhuo jiedu jiangni decoction
Number of subjects: 90
Study 29231546 — intervention group
Group type: COMPARATOR
Intervention: Western medication group with omeprazole (20 mg, twice a day)
Number of subjects: 90
Study 29231546 — intervention group
Group type: COMPARATOR
Intervention: Chinese herbal medicine group (decoction only)
Number of subjects: 90
Study 26243048 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted percutaneous microwave ablation combined with mediastinal radiotherapy with or without chemotherapy (ablation group)
Number of subjects: 98
Study 26243048 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy with or without chemotherapy (RT group)
Number of subjects: 98
Study 26243048 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) in ablation group
Number of subjects: 98
Study 26243048 — intervention group
Group type: COMPARATOR
Intervention: Overall survival (OS) in RT group
Number of subjects: 98
Study 23390005 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Cat individual cognitive‐behavioral therapy (CBT)
Number of subjects: 488
Study 23390005 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management with sertraline (SRT)
Number of subjects: 488
Study 23390005 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT and medication management
Number of subjects: 488
Study 23390005 — intervention group
Group type: COMPARATOR
Intervention: Medication management with pill placebo (PBO)
Number of subjects: 488
Study 23390005 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment conditions (CBT, SRT, COMB, PBO)
Number of subjects: 488
Study 21228609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 30 mg/day
Number of subjects: 50
Study 21228609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21228609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 50
Study 18854204 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 analog BXL746 (acute administration)
Number of subjects: 0
Study 18854204 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic administration of BXL746
Number of subjects: 0
Study 18854204 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 (chronic administration)
Number of subjects: 0
Study 17135584 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus pioglitazone (45 mg daily)
Number of subjects: 55
Study 12972896 — intervention group
Group type: EXPERIMENTAL
Intervention: Boussignac‐CPAP valve
Number of subjects: 30
Study 12972896 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen delivery
Number of subjects: 30
Study 10631204 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural fluid pH
Number of subjects: 433
Study 8623862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cited methodology references
Number of subjects: 206
Study 8623862 — intervention group
Group type: COMPARATOR
Intervention: Lack of methodology reference
Number of subjects: 206
Study 1539481 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.33 mm (29-gauge) Quincke-type spinal needle
Number of subjects: 400
Study 1539481 — intervention group
Group type: COMPARATOR
Intervention: 0.7 mm (22-gauge) Whitacre spinal needle
Number of subjects: 400
Study 3884114 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange therapy
Number of subjects: 20
Study 3884114 — intervention group
Group type: COMPARATOR
Intervention: Sham apheresis
Number of subjects: 20
Study 31521118 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaerytrithyltetranitrate (PETN)
Number of subjects: 0
Study 31521118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29150952 — intervention group
Group type: EXPERIMENTAL
Intervention: CK-2127107 (CK-107)
Number of subjects: 0
Study 29150952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27306932 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based questionnaire (Children's Depression Inventory, CDI)
Number of subjects: 28
Study 27306932 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based questionnaire (Spence Children's Anxiety Scale, SCAS)
Number of subjects: 28
Study 27306932 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil questionnaire (Children's Depression Inventory, CDI)
Number of subjects: 28
Study 27306932 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil questionnaire (Spence Children's Anxiety Scale, SCAS)
Number of subjects: 28
Study 25233645 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut implantation
Number of subjects: 59
Study 25233645 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 59
Study 23597156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive program (13 multi-professional group sessions + medical consultations)
Number of subjects: 180
Study 23597156 — intervention group
Group type: COMPARATOR
Intervention: Traditional program (medical consultations only)
Number of subjects: 180
Study 23597156 — intervention group
Group type: EXPERIMENTAL
Intervention: Both programs
Number of subjects: 180
Study 23597156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive program
Number of subjects: 180
Study 20843951 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 and 20 mg/d)
Number of subjects: 10
Study 20843951 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 and 120 mg/d)
Number of subjects: 10
Study 18841158 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel-Placebo
Number of subjects: 116
Study 18841158 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Imatinib
Number of subjects: 116
Study 17132769 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sunscreen use
Number of subjects: 0
Study 17132769 — intervention group
Group type: COMPARATOR
Intervention: No daily sunscreen use
Number of subjects: 0
Study 12541166 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (Remicade)
Number of subjects: 21
Study 10966959 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (patients with Graves' disease with ophthalmopathy)
Number of subjects: 111
Study 8180301 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID usage
Number of subjects: 174
Study 8180301 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID adverse reaction awareness
Number of subjects: 174
Study 8180301 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor-prescribed NSAID
Number of subjects: 174
Study 8180301 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily NSAID usage
Number of subjects: 174
Study 8180301 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple NSAID usage
Number of subjects: 174
Study 3131571 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 122
Study 3131571 — intervention group
Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GST)
Number of subjects: 122
Study 28925324 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-layer compression therapy (MLCT)
Number of subjects: 16
Study 28925324 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with Cool Pack (CG)
Number of subjects: 16
Study 27300752 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive imagery cognitive bias modification (CBM‐I) training
Number of subjects: 0
Study 27300752 — intervention group
Group type: COMPARATOR
Intervention: Control imagery cognitive bias modification (CBM‐I) condition
Number of subjects: 0
Study 27278477 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 30
Study 27278477 — intervention group
Group type: COMPARATOR
Intervention: Time-matched standard care
Number of subjects: 30
Study 23288353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP) target of 60-65 mm Hg for 30 min
Number of subjects: 16
Study 23288353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP) target of 80-85 mm Hg for 30 min (using norepinephrine infusion)
Number of subjects: 16
Study 23288353 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effects during CPB
Number of subjects: 16
Study 20709569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 22
Study 20709569 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (midazolam and opioids)
Number of subjects: 22
Study 20709569 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 19579987 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (1 mg kg(‐1) daily)
Number of subjects: 30
Study 19579987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17275274 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 3.2g
Number of subjects: 16
Study 17275274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 14963657 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (initial dosages of 60-100 mg for 7-14 days, followed by dose reduction over several months)
Number of subjects: 0
Study 14963657 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous corticosteroids (initial dosages of 500-1,000 mg methylprednisolone at distinct intervals)
Number of subjects: 0
Study 14963657 — intervention group
Group type: COMPARATOR
Intervention: Intravenous corticosteroids
Number of subjects: 0
Study 11844203 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol, 50 microg 6‐hourly
Number of subjects: 435
Study 11844203 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone gel, 1‐2 mg 6‐hourly
Number of subjects: 435
Study 9563868 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 50
Study 9563868 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 50
Study 7625367 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-interferon
Number of subjects: 69
Study 7625367 — intervention group
Group type: EXPERIMENTAL
Intervention: menogaril
Number of subjects: 69
Study 2239715 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 101
Study 2239715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 319204 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg naloxone i.v.
Number of subjects: 4
Study 319204 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 4
Study 30414387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg followed by 90 mg twice daily (ONSET/OFFSET study)
Number of subjects: 303
Study 30414387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily (PEGASUS-TIMI 54 substudy)
Number of subjects: 303
Study 30414387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily (PEGASUS-TIMI 54 substudy)
Number of subjects: 303
Study 30414387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ONSET/OFFSET study)
Number of subjects: 303
Study 30414387 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg followed by 75 mg once daily (ONSET/OFFSET study)
Number of subjects: 303
Study 27923177 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame intervention using Xbox Kinect, 8 weeks, 3 times per week, 40 minutes per session.
Number of subjects: 32
Study 27923177 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 32
Study 25880700 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive educational intervention based on Orem's self-care theory
Number of subjects: 66
Study 25880700 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 66
Study 23212457 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 12579
Study 23212457 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 12579
Study 21798455 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial CAMTS training standards
Number of subjects: 12